Ginkgo Bioworks and Twist Bioscience announced on May 8, 2025, that they have entered into an updated collaboration agreement, renegotiated from a prior contract signed in 2022. This revision impacts the terms of their ongoing partnership.
Under the new terms, Ginkgo Bioworks will receive preferential pricing for DNA products and will no longer have a required minimum purchase volume. This provides Ginkgo with greater flexibility and potentially reduced costs for its DNA product needs.
In exchange, Twist Bioscience receives licenses and assignments for certain long DNA and other technology, as well as related reagents, to complement its existing DNA synthesis portfolio. Ginkgo Bioworks retains the rights to practice the intellectual property transferred to Twist.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.